The weight-loss drug Wegovy may lower the risk of heart attack, stroke or death more than similar medications, according to new research from its maker, Novo Nordisk.
In a study of more than 21,000 patients with obesity and heart disease but no diabetes, those taking Wegovy -- which contains the active ingredient semaglutide -- saw a 57% greater reduction in heart-related risks compared to people taking tirzepatide, the ingredient in Eli Lilly's weight-loss drugs Mounjaro and Zepbound.
The findings were presented at a medical conference and have not yet been peer-reviewed or published. As such, they should be regarded as preliminary.
"This data confirms that semaglutide stands apart as the only available GLP-1-based medication with proven cardiovascular benefits for people living with obesity and cardiovascular disease, without diabetes," Ludovic Helfgott, Novo Nordisk's head of product and portfolio strategy, said in a news release.
Related
